|
|
发表于 2008-6-2 04:17:44
|
显示全部楼层
来自： 加拿大
|
<h1>这是最近美国临床肿瘤协会（ASCO)第44届年度会议的消息，定于2008年5月30日至6月3日在麦考密克展览中心召开。我之所以贴这个贴子，是因为对里面谈的Erbitux药物不甚了解，似乎对肺癌有作用。敬请jimmy112199帮助关注一下6月3日后会议结果，我英语有限，烦请简单做个翻译。</h1><h1></h1><h1></h1><h1>ASCO 2008</h1><p> </p><p>The 44th ASCO annual meeting, set for May 30-June 3, 2008, McCormick Place, Chicago, Illinois, is likely, as always, to generate some exciting cancer stories. Some of the interesting upcoming research follows:</p><p>Eli Lilly are set to unveil data from more than 50 studies: The company will present the latest research findings on Alimta (pemetrexed for injection), Gemzar (gemcitabine HCl for injection), and enzastaurin, an investigational, oral, targeted therapy. The majority of the studies being presented are findings that support Lilly's thoracic cancer research. Of note is a pivotal Phase III study (ASCO Abstract # 8060) that has demonstrated a key correlation between lung cancer histology (tissue type), treatment choice and patient outcome. It will be one of the studies featured on Thursday, May 15 in ASCO's live online presscast. The virtual press event will be the first time ASCO has selected researchers to present key abstracts prior to its annual meeting.</p><p>The drug Erbitux, from ImClone and Merck KGaA, is likely to cause some media and business interest as results from a new trial known as ‘Flex’ are announced. The trial, for treatment of lung cancer, has already been announced by Merck as a success, but the extent to which Erbitux improves survival is not yet known. Erbitux will go head to head with Genetech’s Avastin so trial results are especially important for the markets.</p><p><br/>Ipilimumab has shown increasing efficacy with time for melanoma patients, according to its manufacturers Medarex. Phase III trial results are to be announced.</p><p><br/>Avastin for first-line metastatic breast cancer patients is also set to garner attention with the announcement of key data from the ‘Avado’ trial, an ongoing randomized, double-blind, placebo-controlled, US, multicentre phase III trial that randomized 705 patients to receive docetaxel at a dose of 100 mg/m2 every 3 weeks with either placebo, Avastin at 7.5 mg/kg or Avastin at 15 mg/kg.</p><p><br/>Apart from drug trial announcements, the ASCO 2008 meeting will also provide a forum for the latest in medical engineering, genetics, epidemiology, palliative care and advice from patient advocacy groups and key opinion leaders alike.</p> |
|
IP卡
狗仔卡
hase
显身卡
楼主